Loading...
The 2018 Global Initiative for Asthma update, used in Europe, recommends two new treatment options for uncontrolled asthma that are not included in the National Asthma Education and Prevention Program (NAEPP) guideline that is used currently in the U.S. Now, in two meta-analyses, researchers have examined the evidence to support these new options.
In one meta-analysis, researchers evaluated 15 randomized trials (7122 patients; age, ≥12 years) in which tiotropium (a long-acting muscarinic antagonist [LAMA]) was added to inhaled corticosteroid (ICS) monotherapy or to ICS-plus–long-acting β-agonist (LABA) dual therapy, with the primary endpoint of asthma exacerbations that required oral corticosteroids. Patients treated with ICS plus tiotropium…